平博

R&D and Innovation

HomeInnovation and DevelopmentR&D and Innovation

8


No.1 in Domestic Market
Share (from IQVIA data)

70

+

New Development Projects

14


Products with Annual Sales
Exceeding 100 Million RMB

13


Innovative Drugs

13


biosimilars

10

+

Consistency Evaluation Products

92


Authorized Patents

8


No.1 in Domestic Market
Share (from IQVIA data)

70

+

New Development Projects

14


Products with Annual Sales
Exceeding 100 Million RMB

13


Innovative Drugs

10

+

Consistency Evaluation Products

92


Authorized Patents

R&D and Innovation

Based on efficient and high-quality R&D, Wanbang Biopharma is continuously committed to develop "affordable innovation" and addressing unmet disease treatment need. Wanbang Biopharma invests exceed 10% of the annual sales revenues for drug research and development. In 2019, R&D investment increased by 92% year on year growth and continues to grow.

Scientific Research Achievements

At present, Wanbang Biophrma R&D pipeline has 72 projects which include 13 innovative drugs, 13 biosimilars and 21 consistency evaluation projects. There are 92 authorized patents including 52 invention patents.
Ranking  

27


Ranked in the top 100 new drug applications of drug think tanks

40+


More Than 40 National Patent Applications Annually

12


National, Provincial and Ministerial Research Projects

Clinical trials are under way for several innovative drugs, generics and biologics. In the consistency evaluation project of generic drugs, many products are in the leading position. Wansuping (Glimepiride Tablet) 、Shilida (Amlodipine Tablet)、Youlitong (Febuxostat Tablet)and Bang Zhi(Pitavastatin Calcium Tablets) 、Zhaohuixian(Bicalutamide Tablets) were approved firstly. The Youlitong (Febuxostat Tablet), type 3.1 new drug application, approved in 2013, has become the key product of Wanbang Biopharma.
Youlitong
Generic Name: Febuxostat Tablet

Two R&D Platforms

Biological Drug R&D Platform
Chemical Drug R&D Platform

International First-class Innovation Platform

  • Postdoctoral Workstation
  • Jiangsu Key R&D Enterprise Institutions
  • Jiangsu Academician Workstation
  • Jiangsu Recombinant Protein Drug Engineering Center
  • Jiangsu Enterprise Technology Center
  • Jiangsu Engineering Research Center for Diabetic Drugs
  • Jiangsu Strategic Emerging Industry Innovation Demonstration Enterprise
  • Top 100 Comprehensive Strengths of China's Chemical and Pharmaceutical Industrial Enterprises in 2019(27th)

R&D Team

Nearly  300

R&D Personnel

Nearly  

7.9%

Proportion of R&D Personnel
In the Total Number of Employees

52%

Proportion of Senior Researchers
With Master/PhD Degrees

    1. 平博